• Nineteen patients with Raynaud's phenomenon in conjunction with progressive systemic sclerosis were given either prazosin hydrochloride (1 mg orally three times a day) or a placebo for eight weeks, after which the treatment procedure was reversed for four weeks. Prazosin was shown to be effective in reducing both the frequency and the severity of vasospasm reported by the patients.
(Arch Dermatol 1984;120:329-331)
Surwit RS, Gilgor RS, Allen LM, Duvic M. A Double-blind Study of Prazosin in the Treatment of Raynaud's Phenomenon in Scleroderma. Arch Dermatol. 1984;120(3):329–331. doi:10.1001/archderm.1984.01650390051010
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.